Table 1.
Clinical trials of mRNA encoding TAAs.
| Antigen | Brand | Title | Conditions | NCT Number | Phase | Study Start | Status | ||
|---|---|---|---|---|---|---|---|---|---|
| NY-ESO-1, MAGE-C3, tyrosinase, TPTE | BNT111 | Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | Melanoma Stage III/IV | NCT04526899 | Phase 2 | May 19, 2021 | Recruiting | ||
| RBL038, RBL039, RBL-040, RBL-041, RBL-045 | BNT112 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) | Prostate Cancer | NCT04382898 | Phase 1/2 | December 19, 2019 | Recruiting | ||
| HPV16(+) E6、E7 | BNT113 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Head and Neck Cancer Recurrent Head and Neck Cancer | NCT04534205 | Phase 2 | January 7, 2021 | Recruiting | ||
| antigen commonly expressed by NSCLC cells | BNT116 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | NSCLC | NCT05142189 | Phase 1 | April 2022 | Not yet recruiting | ||
| 3 OC TAA | W_ova1 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy | Ovarian Cancer | NCT04163094 | Phase 1 | November 25, 2019 | Recruiting | ||
| PSA, PSCA, PSMA, STEAP1 | CV9103 | Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease | Prostate cancer | NCT00831467 | Phase 1/2 | January 2009 | Completed | ||
| PSA, PSCA, PSMA, STEAP1, PAP, MUC1 | CV9104 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | Prostate cancer | NCT01817738 | Phase 1/2 | August 2012 | Terminated | ||
| MAGE-C1, MAGEC2, NY-SEO-1, survivin, 5 T4 | CV9201 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non-Small Cell Lung Cancer(NSCLC) | Stage IIIB/IV NSCLC | NCT00923312 | Phase 1/2 | May 2009 | Completed | ||
| NY-ESO-1, MAGEC1, MAGE-C2, 5 T4, survivin, MUC1 | CV9202 | Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC | NSCLC | NCT03164772 | Phase 1/2 | December 20, 2017 | Completed | ||